Pulse Biosciences Taps New CFO as It Ramps Up PFA Market Push

Pulse Biosciences has named Jon Skinner as its new Chief Financial Officer, continuing a series of executive changes that saw a new CEO, Paul LaViolette, take over just last month. The appointment follows a period of leadership turnover, including the resignation of former CEO Burke Barrett after only seven months and the departure of former CFO Sandra Gardiner, who later filed an arbitration claim against the company. Skinner, who previously held financial roles at Copeland, Imperative Care, and Teleflex, steps into the role as Pulse moves toward commercialization of its pulsed field ablation (PFA) technology.

Pulse is positioning its PFA platform as a faster and more efficient alternative to existing ablation technologies, directly competing with industry leaders like Boston Scientific and Medtronic. With multiple pivotal clinical trials set to launch this year and a strong cash position of $118 million, the company is preparing for significant growth. Investors responded positively to Skinner’s appointment, sending Pulse’s stock price up nearly 15%, reflecting confidence in the company’s future as it seeks to capitalize on the growing demand for PFA in atrial fibrillation and other medical applications.